UPADACITINIB

upadacitinib 30 mg modified release tablet, 28

UPADACITINIB (12836N)

upadacitinib 30 mg modified release tablet, 28
12836N
Body System:
Manner of administration:Oral
General Schedule
Authority Required

Restriction

Indication: Chronic severe atopic dermatitis
Treatment phase: Initial treatment with this drug of the whole body

Restriction

Indication: Chronic severe atopic dermatitis
Treatment phase: Initial treatment with this drug of the face and/or hands
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 28 # of repeats: 4 DPMQ: $1,977.47 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Rinvoq